@article{10.11648/j.ijbse.20160405.11,
  author = {Mahendra Kumar Trivedi and Alice Branton and Dahryn Trivedi and Gopal Nayak and Michael Peter Ellis and James Jeffery Peoples and James Joseph Meuer and Johanne Dodon and John Lawrence Griffin and John Suzuki and Joseph Michael Foty and Judy Weber and Julia Grace McCammon and Karen Brynes Allen and Kathryn Regina Sweas and Lezley Jo-Anne Wright and Lisa A. Knoll and Madeline E. Michaels and Margaret Kweya Wahl and Mark E. Stutheit and Michelle Barnard and Muriel Mae Ranger and Paromvong Sinbandhit and V. J. Kris Elig and Sambhu Charan Mondal and Snehasis Jana},
  title = {Evaluation of Pro-Inflammatory Cytokines Expression in Mouse Splenocytes After Co-Incubation with the Biofield Energy Treated Formulation: Impact of the Trivedi Effect®},
  journal = {International Journal of Biomedical Science and Engineering},
  volume = {4},
  number = {5},
  pages = {40-49},
  doi = {10.11648/j.ijbse.20160405.11},
  url = {https://doi.org/10.11648/j.ijbse.20160405.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbse.20160405.11},
  abstract = {With the increasing popularity of herbomineral preparations in healthcare, a new proprietary herbomineral formulation was formulated with ashwagandha root extract and minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the herbomineral test formulation using mice splenocytes. The test formulation was divided into two parts. One part was the control without the Biofield Treatment. The other part was labelled the Biofield Treated sample, which received the Biofield Energy Healing Treatment remotely from twenty renowned Biofield Energy Healers. The splenocyte cells were exposed with the test formulation at ranges of 0.00001053 to 10.53 µg/mL for cell viability by MTT assay, with cell viability ranging from 77.50% to 176.52%. TNF-α was significantly inhibited by 15.88%, 15.28%, 12.30%, 12.60%, and 22.72% at 0.00001053, 0.001053, 0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the vehicle control (VC). TNF-α was significantly reduced by 2.33% and 8.35% at 1.053 and 10.53 µg/mL, respectively compared to the untreated test formulation. IL-1β was significantly reduced by 30.81%, 27.36%, 23.92%, 18.40%, 11.27%, and 21.16% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. IL-1β was significantly reduced by 48.63% (p≤0.001) and 15.28% at 0.00001053 and 0.0001053 µg/mL, respectively in the Biofield Treated test formulation compared to the untreated test formulation. MIP-1α expression was inhibited by the Biofield Treated test formulation and showed immunosuppressive activity at 0.01053, 0.1053, 1.053, and 10.53 µg/mL by 22.33%, 16.25%, 15.58%, and 21.83%, respectively compared to the VC. The Biofield Treated test formulation significantly reduced the MIP-1α expression by 13.27% and 15.67% (p<0.05) at 0.01053 and 10.53 µg/mL, respectively compared to the untreated test formulation. The results showed the expression of IFN-γ was significantly reduced by 33.45%, 25.38%, 37.15%, 27.74%, 32.44%, 23.03%, and 44.21% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. Further, the IFN-γ level was significantly decreased by 19.02% at 10.53 µg/mL in the Biofield Treated test formulation compared to the untreated test formulation. Overall, the results demonstrate that The Trivedi Effect® Biofield Energy Healing (TEBEH) significantly enhanced the anti-inflammatory and immunomodulatory properties of the treated formulation, and may also be useful in organ transplants, anti-aging, and stress management by improving overall health and quality of life.},
 year = {2016}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of Pro-Inflammatory Cytokines Expression in Mouse Splenocytes After Co-Incubation with the Biofield Energy Treated Formulation: Impact of the Trivedi Effect®
AU  - Mahendra Kumar Trivedi
AU  - Alice Branton
AU  - Dahryn Trivedi
AU  - Gopal Nayak
AU  - Michael Peter Ellis
AU  - James Jeffery Peoples
AU  - James Joseph Meuer
AU  - Johanne Dodon
AU  - John Lawrence Griffin
AU  - John Suzuki
AU  - Joseph Michael Foty
AU  - Judy Weber
AU  - Julia Grace McCammon
AU  - Karen Brynes Allen
AU  - Kathryn Regina Sweas
AU  - Lezley Jo-Anne Wright
AU  - Lisa A. Knoll
AU  - Madeline E. Michaels
AU  - Margaret Kweya Wahl
AU  - Mark E. Stutheit
AU  - Michelle Barnard
AU  - Muriel Mae Ranger
AU  - Paromvong Sinbandhit
AU  - V. J. Kris Elig
AU  - Sambhu Charan Mondal
AU  - Snehasis Jana
Y1  - 2016/12/29
PY  - 2016
N1  - https://doi.org/10.11648/j.ijbse.20160405.11
DO  - 10.11648/j.ijbse.20160405.11
T2  - International Journal of Biomedical Science and Engineering
JF  - International Journal of Biomedical Science and Engineering
JO  - International Journal of Biomedical Science and Engineering
SP  - 40
EP  - 49
PB  - Science Publishing Group
SN  - 2376-7235
UR  - https://doi.org/10.11648/j.ijbse.20160405.11
AB  - With the increasing popularity of herbomineral preparations in healthcare, a new proprietary herbomineral formulation was formulated with ashwagandha root extract and minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the herbomineral test formulation using mice splenocytes. The test formulation was divided into two parts. One part was the control without the Biofield Treatment. The other part was labelled the Biofield Treated sample, which received the Biofield Energy Healing Treatment remotely from twenty renowned Biofield Energy Healers. The splenocyte cells were exposed with the test formulation at ranges of 0.00001053 to 10.53 µg/mL for cell viability by MTT assay, with cell viability ranging from 77.50% to 176.52%. TNF-α was significantly inhibited by 15.88%, 15.28%, 12.30%, 12.60%, and 22.72% at 0.00001053, 0.001053, 0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the vehicle control (VC). TNF-α was significantly reduced by 2.33% and 8.35% at 1.053 and 10.53 µg/mL, respectively compared to the untreated test formulation. IL-1β was significantly reduced by 30.81%, 27.36%, 23.92%, 18.40%, 11.27%, and 21.16% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. IL-1β was significantly reduced by 48.63% (p≤0.001) and 15.28% at 0.00001053 and 0.0001053 µg/mL, respectively in the Biofield Treated test formulation compared to the untreated test formulation. MIP-1α expression was inhibited by the Biofield Treated test formulation and showed immunosuppressive activity at 0.01053, 0.1053, 1.053, and 10.53 µg/mL by 22.33%, 16.25%, 15.58%, and 21.83%, respectively compared to the VC. The Biofield Treated test formulation significantly reduced the MIP-1α expression by 13.27% and 15.67% (p<0.05) at 0.01053 and 10.53 µg/mL, respectively compared to the untreated test formulation. The results showed the expression of IFN-γ was significantly reduced by 33.45%, 25.38%, 37.15%, 27.74%, 32.44%, 23.03%, and 44.21% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. Further, the IFN-γ level was significantly decreased by 19.02% at 10.53 µg/mL in the Biofield Treated test formulation compared to the untreated test formulation. Overall, the results demonstrate that The Trivedi Effect® Biofield Energy Healing (TEBEH) significantly enhanced the anti-inflammatory and immunomodulatory properties of the treated formulation, and may also be useful in organ transplants, anti-aging, and stress management by improving overall health and quality of life.
VL  - 4
IS  - 5
ER  - 

Copy | Download